announced the first clinical data evaluating its TGFβR2×PD-1 bispecific antibody (INCA33890) for patients with microsatellite stable (MSS) colorectal cancer; and its potent, selective and orally bioavailable KRAS G12D inhibitor (INCB161734) for patients with KRAS G12D mutations, specifically pancreatic ductal adenocarcinoma…
For decades, traditional adrenaline auto-injectors (AAIs) have been the only available treatment for anaphylaxis—a life-threatening allergic reaction.1,2 Yet from today, the UK’s first needle-free emergency anaphylaxis treatment, the EURneffy® nasal adrenaline spray, is available on prescription.3 EURneffy® 2 mg nasal spray offers a…
(Nasdaq: EXEL) today announced detailed results from STELLAR-303, a global phase 3 pivotal trial evaluating zanzalintinib in combination with atezolizumab (Tecentriq®) versus regorafenib in patients with previously treated non-microsatellite instability (MSI)-high metastatic colorectal cancer (CRC). As previously announced, the study met…
DATROWAY® Demonstrates Significant Survival Benefit Over Chemotherapy in First-Line Metastatic Triple-Negative Breast Cancer in TROPION-Breast02 Trial Positive results from the pivotal TROPION-Breast02 phase 3 trial have shown that DATROWAY® (datopotamab deruxtecan) delivers a statistically significant and clinically meaningful improvement in…
DESTINY-Breast05 Phase III Trial Demonstrates ENHERTU® Significantly Reduces Recurrence Risk in High-Risk HER2-Positive Early Breast Cancer Positive results from the DESTINY-Breast05 Phase III trial have demonstrated that ENHERTU® (fam-trastuzumab deruxtecan-nxki) provides a highly statistically significant and clinically meaningful improvement in…
Genmab Reports Promising New Data Showing Rina-S® Demonstrates Strong Anti-Tumor Activity in Advanced Endometrial Cancer Genmab A/S (Nasdaq: GMAB) announced new and encouraging results from its Phase 1/2 RAINFOL™-01 clinical trial evaluating rinatabart sesutecan (Rina-S®), an investigational folate receptor alpha…
Eikon Therapeutics, Inc., a late-stage clinical biopharmaceutical company focused on integrating advanced engineering with cutting-edge laboratory and in silico research to accelerate drug discovery, today announced that new data from its ongoing Phase 2 study of EIK1001 (TeLuRide-005) will be…
Zoetis Inc. today announced that Health Canada has approved Lenivia® (izenivetmab injection) for the treatment of pain associated with osteoarthritis (OA) in dogs. Lenivia represents a novel monoclonal antibody therapy, developed over a decade of rigorous scientific research, designed to…
Augurex Life Sciences Corp., a leading innovator in autoimmune-based diagnostics, today announced a strategic partnership with MitogenDx, a Canadian specialty laboratory focused on autoimmune and rheumatology testing. Under the agreement, MitogenDx will offer Augurex’s JOINTstat® blood test, significantly expanding access…
Lasso, a next-generation food technology company, today officially launched with the unveiling of its proprietary Lasso SpinTech, a physics-based system designed to revolutionize how modern packaged foods are made. The breakthrough technology blends protein and fiber in a completely new…